| Literature DB >> 30201538 |
Ian M Fearon1, Alison C Eldridge2, Nathan Gale2, Mike McEwan2, Mitchell F Stiles3, Elaine K Round4.
Abstract
E-cigarettes are battery-powered electronic devices from which users can inhale nicotine following its aerosolisation from a liquid solution. Some regulators and public health bodies consider e-cigarettes as potentially playing a major role in tobacco harm reduction. Their ability to provide nicotine to smokers in both amount and in a manner and form generally similar to cigarette smoking have been proposed as key components to help smokers reduce or cease the use of combustible cigarettes. Nicotine pharmacokinetic studies of e-cigarettes have been performed for a number of years and are beginning to show how nicotine delivery is evolving as the products themselves evolve. In this review, we provide a critical overview of the literature to describe what is known about nicotine delivery from e-cigarettes. We will discuss how the progression of e-cigarette design, development, and user familiarity has allowed increases in nicotine availability to the user, in the context of how much and how rapidly nicotine is delivered during acute-use periods. This review will also provide insight into current research gaps and highlight the potential utility of modelling and the standardisation of methodologies used to assess nicotine delivery to facilitate identification of products that are best suited to displace cigarette smoking among adult smokers.Entities:
Keywords: Clinical studies; E-cigarette; Human; Nicotine; Pharmacokinetics
Mesh:
Substances:
Year: 2018 PMID: 30201538 DOI: 10.1016/j.yrtph.2018.09.004
Source DB: PubMed Journal: Regul Toxicol Pharmacol ISSN: 0273-2300 Impact factor: 3.271